1 completed, 1 recruiting. 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
Follow Guo ShiWei: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AI-Assisted Non-Contrast CT for Multi-Cancer Screening AI-Assisted Non-Contrast CT for Multi-Cancer Screening - Lung Cancers, Liver Cancer | Not applicable | Recruiting | Guo ShiWei | 1000000 | 2024-10-07 | 2024-10-09 |
| Mesenchymal CTC Ratio Dynamics Predicts Response and Survival in Pancreatic Ductal Adenocarcinoma With Neoadjuvant/Conversion Therapy surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines - Pancreatic Ductal Adenocarcinoma (PDAC), Circulating Tumor Cells (CTCs) | Completed | Guo ShiWei | 300 | 2018-07-10 | 2026-01-12 |
Breast Neoplasms (1) · Colonic Neoplasms (1) · Disease (1) · Esophageal Neoplasms (1) · Liver Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplastic Cells, Circulating (1) · Pancreatic Neoplasms (1) · Stomach Neoplasms (1)
Surgical Procedures, Operative (1)
China (2)
Jin Gang, M.D. (1)